A detailed history of Lazari Capital Management, Inc. transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Lazari Capital Management, Inc. holds 13,000 shares of PDSB stock, worth $28,600. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,000
Previous 13,000 -0.0%
Holding current value
$28,600
Previous $38.1 Million 30.38%
% of portfolio
0.02%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Sep 09, 2024

BUY
$2.55 - $4.02 $5,100 - $8,039
2,000 Added 18.18%
13,000 $38.1 Million
Q1 2024

Jun 24, 2024

SELL
$3.85 - $6.59 $3,850 - $6,590
-1,000 Reduced 8.33%
11,000 $43.6 Million
Q4 2023

Feb 27, 2024

BUY
$3.95 - $6.58 $3,950 - $6,580
1,000 Added 9.09%
12,000 $59.6 Million
Q2 2023

Jul 20, 2023

BUY
$5.03 - $9.9 $55,330 - $108,900
11,000 New
11,000 $55.3 Million

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $62.6M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Lazari Capital Management, Inc. Portfolio

Follow Lazari Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazari Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Lazari Capital Management, Inc. with notifications on news.